Ofloxacin 400mg tablets

200mg/100ml

Ciprofloxacin 400mg/200ml infusion polyethylene bottles

400mg/200ml

Moxifloxacin 400mg/250ml infusion polyethylene bottles

400mg/250ml

Levofloxacin 500mg/100ml infusion polyethylene bottles

500mg/100ml

Levofloxacin 125mg/5ml oral solution

Oral solution

125mg/5ml

Drug monograph — bnf.nice.org.uk

Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Show details

Loading prescribing data...

Clinical guidelines and formulary information

British National Formulary

Ofloxacin

BNF

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

NICE clinical guidance(3)

Prostatitis (acute): antimicrobial prescribing (NG110)

NG110

Guidance

Updated Oct 2018

Urinary tract infection (lower): antimicrobial prescribing (NG109)

NG109

Guidance

Updated Oct 2018

Urinary tract infection (recurrent): antimicrobial prescribing (NG112)

NG112

Guidance

Updated Dec 2024

Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Ofloxacin

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

41953511000001104

dm+d ID

41953511000001104

VTM (Virtual Therapeutic Moiety)

776973005

VMP (Virtual Medicinal Product)

41953511000001104

BNF code

05011200

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

J01MA01

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

75 found

Half-life

9 hours

Mechanism

Ofloxacin acts on DNA gyrase and toposiomerase IV, enzymes which, like human top…

Food interactions

2 warnings

Human targets

1 target

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

98%

Bioavailability of ofloxacin in the tablet formulation is approximately 98%

Half-life

9 hours

9 hours

Protein binding

32%

Metabolism

Hepatic

Elimination

65%

Ofloxacin is mainly eliminated by renal excretion, where between 65% and 80% of an administered oral dose of ofloxacin is excreted unchanged via urine within 48 hours of dosing.…

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Investigational

Small molecule

About this compound

A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.

Properties:

solid

Avg. mass: 361.37 Da

View FDA drug label

DrugBank indication

For the treatment of infections (respiratory tract, kidney, skin, soft tissue, UTI), urethral and cervical gonorrhoea.

Also known as(63)

8-Fluoro-3-methyl-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylic acid

Ofloxacin

Ofloxacine

Ofloxacino

Ofloxacinum

OFLX

5.6.2.2

5.99.1.3

Dosage forms(64)

Solution (Auricular (otic))

Ointment (Ophthalmic) — 0.3 %

Solution / drops (Ophthalmic) — 3 MG/ML

Suspension (Ophthalmic)

Tablet (Oral)

Tablet (Oral) — 400.00 mg

Tablet, film coated (Oral) — 200.00 MG

Ointment (Ophthalmic)

Molecular properties(19)

Drug interactions(1003)

Known interactions with other medications. Always consult a healthcare professional.

Ivabradine

Moderate

DB09083

Ivabradine may increase the QTc-prolonging activities of Ofloxacin.

Troglitazone

Moderate

DB00197

Troglitazone may decrease the excretion rate of Ofloxacin which could result in a higher serum level.

Reserpine

Moderate

DB00206

Reserpine may decrease the excretion rate of Ofloxacin which could result in a higher serum level.

Progesterone

Moderate

DB00396

Progesterone may decrease the excretion rate of Ofloxacin which could result in a higher serum level.

Chlorpromazine

Moderate

DB00477

Chlorpromazine may decrease the excretion rate of Ofloxacin which could result in a higher serum level.

Celecoxib

Moderate

DB00482

Celecoxib may decrease the excretion rate of Ofloxacin which could result in a higher serum level.

Cimetidine

Moderate

DB00501

Cimetidine may decrease the excretion rate of Ofloxacin which could result in a higher serum level.

Bosentan

Moderate

DB00559

Bosentan may decrease the excretion rate of Ofloxacin which could result in a higher serum level.

Tipranavir

Moderate

DB00932

Tipranavir may decrease the excretion rate of Ofloxacin which could result in a higher serum level.

Ethinylestradiol

Moderate

DB00977

Ethinylestradiol may decrease the excretion rate of Ofloxacin which could result in a higher serum level.

Glyburide

Moderate

DB01016

Glyburide may decrease the excretion rate of Ofloxacin which could result in a higher serum level.

Ketoconazole

Moderate

DB01026

Ketoconazole may decrease the excretion rate of Ofloxacin which could result in a higher serum level.

Ursodeoxycholic acid

Moderate

DB01586

Ursodeoxycholic acid may decrease the excretion rate of Ofloxacin which could result in a higher serum level.

Cholic Acid

Moderate

DB02659

Cholic Acid may decrease the excretion rate of Ofloxacin which could result in a higher serum level.

Fusidic acid

Moderate

DB02703

Fusidic acid may decrease the excretion rate of Ofloxacin which could result in a higher serum level.

Simeprevir

Moderate

DB06290

Simeprevir may decrease the excretion rate of Ofloxacin which could result in a higher serum level.

Lenvatinib

Moderate

DB09078

Lenvatinib may decrease the excretion rate of Ofloxacin which could result in a higher serum level.

Valinomycin

Moderate

DB14057

Valinomycin may decrease the excretion rate of Ofloxacin which could result in a higher serum level.

Olmesartan

Moderate

DB00275

Olmesartan may decrease the excretion rate of Ofloxacin which could result in a higher serum level.

Pralsetinib

Moderate

DB15822

Pralsetinib may decrease the excretion rate of Ofloxacin which could result in a higher serum level.

Didanosine

Moderate

DB00900

Didanosine can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.

Probenecid

Moderate

DB01032

Probenecid may decrease the excretion rate of Ofloxacin which could result in a higher serum level.

Quinapril

Moderate

DB00881

Quinapril can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.

Calcium acetate

Moderate

DB00258

Calcium acetate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.

Sevelamer

Moderate

DB00658

Sevelamer can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.

Iron Dextran

Moderate

DB00893

Iron Dextran can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.

Calcium

Moderate

DB01373

Calcium can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.

Calcium carbonate

Moderate

DB06724

Calcium carbonate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.

Lanthanum carbonate

Moderate

DB06792

Lanthanum carbonate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.

Ferric carboxymaltose

Moderate

DB08917

Ferric carboxymaltose can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.

Iron sucrose

Moderate

DB09146

Iron sucrose can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.

Ferric pyrophosphate

Moderate

DB09147

Ferric pyrophosphate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.

Calcium citrate

Moderate

DB11093

Calcium citrate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.

Calcium gluconate

Moderate

DB11126

Calcium gluconate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.

Ferric sulfate

Moderate

DB11171

Ferric sulfate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.

Ferric cation

Moderate

DB13949

Ferric cation can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.

Tetraferric tricitrate decahydrate

Moderate

DB14520

Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.

Lanthanum III cation

Moderate

DB14579

Lanthanum III cation can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.

Calcium polycarbophil

Moderate

DB14684

Calcium polycarbophil can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.

Ferric oxyhydroxide

Moderate

DB14695

Ferric oxyhydroxide can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.

Sucralfate

Moderate

DB00364

Sucralfate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.

Zolmitriptan

Moderate

DB00315

The metabolism of Zolmitriptan can be decreased when combined with Ofloxacin.

Nitrofurantoin

Moderate

DB00698

The therapeutic efficacy of Ofloxacin can be decreased when used in combination with Nitrofurantoin.

Mycophenolic acid

Unknown severity

DB01024

The serum concentration of Mycophenolic acid can be decreased when it is combined with Ofloxacin.

Picosulfuric acid

Moderate

DB09268

The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ofloxacin.

Insulin human

Moderate

DB00030

The therapeutic efficacy of Insulin human can be increased when used in combination with Ofloxacin.

Insulin lispro

Moderate

DB00046

The therapeutic efficacy of Insulin lispro can be increased when used in combination with Ofloxacin.

Insulin pork

Moderate

DB00071

The therapeutic efficacy of Insulin pork can be increased when used in combination with Ofloxacin.

Glimepiride

Moderate

DB00222

The therapeutic efficacy of Glimepiride can be increased when used in combination with Ofloxacin.

Sulfisoxazole

Moderate

DB00263

The therapeutic efficacy of Sulfisoxazole can be increased when used in combination with Ofloxacin.